Compare · JHB vs PHO
JHB vs PHO
Side-by-side comparison of Nuveen High Income November 2021 Target Term Fund (JHB) and Invesco Water Resources ETF (PHO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JHB and PHO operate in n/a (n/a), so they compete in similar markets.
- JHB carries a market cap of $525.4M.
Invesco Water Resources ETF
The investment seeks to track the investment results (before fees and expenses) of the NASDAQ OMX US Water IndexSM (the "underlying index"). The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index seeks to track the performance of companies that create products designed to conserve and purify water for homes, businesses and industries. The underlying index may include common stocks, ordinary shares, American depositary receipts ("ADRs"), shares of beneficial interest and tracking stocks. The fund is non-diversified.
Latest JHB
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
- Nuveen Corporate Income November 2021 Target Term Fund Announces Termination and Liquidation
- SEC Form 25-NSE filed by Nuveen High Income November 2021 Target Term Fund
- Nuveen Corporate Income November 2021 Target Term Fund Announces Liquidation Details
- SEC Form N-CSRS filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form N-PX filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form 3 filed by Lancellotta Amy B.R.
- Nuveen Corporate Income November 2021 Target Term Fund Announces Wind-Up Period
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
Latest PHO
- Software Provider Roper Tech Boosts Annual Outlook Following Q1 Performance: The Details
- Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN
- Photocure ASA: Results for the fourth quarter of 2023
- Photocure Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China
- Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China
- Photocure to present at four investor conferences in November/December 2023
- Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress
- Photocure ASA: Change of Board Composition
- Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
- Photocure ASA: Results for the second quarter and first half of 2023